Retatrutide Side Effects: What Clinical Trials Have Reported So Far

Educational content for licensed healthcare professionals. Not medical advice; dosing and treatment decisions belong to the prescribing clinician.

Retatrutide side effects are known only from clinical trials, because retatrutide is still an investigational drug with no FDA label. So far the picture looks like the rest of the incretin class, dominated by gastrointestinal effects during dose escalation, plus a few signals specific to its glucagon-receptor activity. This post summarizes what trials have reported, what class warnings are likely to apply, and what is still unknown.

For background on the compound itself, see the retatrutide library page.

Common Retatrutide Side Effects

Gastrointestinal Effects

The most frequently reported retatrutide side effects in the phase 2 trials were gastrointestinal:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Decreased appetite and early fullness (partly the intended effect)

These effects were dose-related, mostly mild to moderate, and concentrated during dose escalation. The trials explored lower starting doses to improve tolerability. That matches experience with tirzepatide and semaglutide, where slow titration is the main tool for managing GI symptoms.

These labels describe relative frequency in published trial reports, not incidence rates, and not predictions for an individual patient.

Heart Rate Increases

The phase 2 trials reported dose-dependent increases in heart rate. In the obesity trial, the increase peaked partway through treatment and then declined. Modest heart rate increases are also seen with other incretin drugs. Their long-term significance for retatrutide will be clarified by larger and longer trials. In practice this is a parameter to monitor, especially in patients with arrhythmia history.

Side Effects Linked to the Mechanism

The Glucagon Component

Retatrutide activates GLP-1, GIP and glucagon receptors. Glucagon agonism adds energy expenditure and fat mobilization, including in the liver. A phase 2 substudy in participants with fatty liver reported marked reductions in liver fat. But glucagon also raises hepatic glucose output. In retatrutide the GLP-1 and GIP activity offsets that effect, but it is one reason the site's three-way comparison flags glycemic effects for careful observation.

Rapid Weight Loss Effects

The larger the weight loss, the more relevant the consequences of rapid weight loss become:

• Lean mass loss. A meaningful share of weight lost on incretin therapy can be lean tissue. Protein intake and resistance training matter.
• Gallbladder disease. Rapid weight loss raises the risk of gallstones.
• Dehydration. Vomiting and diarrhea can cause volume depletion, a risk to kidney function in vulnerable patients.

Class Warnings Likely to Apply

The approved incretin drugs carry warnings that are reasonable to anticipate for retatrutide, even though its own label doesn't exist yet:

Our weight-loss peptide safety guide covers monitoring across the class.

Risks From Unregulated Retatrutide

Retatrutide has no legitimate compounding pathway (see our retatrutide compounding guide). Some patients who report side effects are using research-chemical product. With that material, clinical trial safety data may not apply at all:

• The vial may not contain retatrutide, or not the stated amount.
• Contaminants and non-sterile preparation can cause reactions the trials never saw.
• Dosing errors are more likely when the concentration is uncertain. See retatrutide dosage for why research-vial dosing charts have no clinical basis.

A patient reporting unusual symptoms on unregulated retatrutide should have the source treated as part of the clinical picture.

What Is Still Unknown

• Long-term safety. Phase 2 trials ran for about a year; multi-year data will come from phase 3 and later.
• Cardiovascular outcomes. Hard-outcome data like semaglutide's are not yet available.
• Rare events. Uncommon adverse effects typically surface only in large populations and post-marketing surveillance.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner. Prescribers can start at For Providers.

Frequently Asked Questions

What are the most common side effects of retatrutide?

In clinical trials the most common were gastrointestinal: nausea, diarrhea, vomiting and constipation. They were mostly mild to moderate, dose-related and concentrated during dose escalation.

Does retatrutide raise heart rate?

The phase 2 trials reported dose-dependent heart rate increases that peaked partway through treatment and then declined. Heart rate is a parameter to monitor, particularly in patients with arrhythmia history.

Are retatrutide side effects worse than tirzepatide's?

The side effects are broadly similar in character. Direct comparisons require head-to-head trials. The glucagon component adds considerations of its own, including effects on the liver and on glucose.

Is retatrutide safe?

Its safety is still being established in phase 3 trials, and it is not FDA-approved. Retatrutide from unregulated sources carries additional risks from unknown content and sterility.

What should a patient on research-grade retatrutide do about side effects?

They should tell their clinician both the symptoms and the source. Unregulated material may not match what trials studied, so the clinician should also discuss FDA-approved alternatives.